Immunotherapy Pipeline UBI is actively developing synthetic peptide-based biologics for chronic and infectious diseases including Alzheimer’s, AIDS, and allergy, plus vaccines. Potential sales opportunities exist in partnering or contract development for novel peptide therapies and vaccine formulations, as well as opportunities to license or co-develop biosimilar strategies as patents expire.

Diagnostics and Screening The company has a line of blood screening diagnostics and has commercialized a synthetic peptide vaccine. This opens avenues for diagnostic collaborations, contract manufacturing for diagnostic kits, and joint ventures to expand screening capabilities in clinical and supply chain settings.

Contract Manufacturing UBI leverages pharmaceutical contract manufacturing through UBI-Asia, presenting a clear sales route for laboratory-scale to GMP manufacturing services, process development, formulation, and fill-finish capabilities to biopharma customers seeking external manufacturing capacity.

Biosimilar Platform The platform technologies enabling biosimilar development of widely used protein and antibody drugs align with market trends of patent expirations. Opportunities exist to offer biosimilar development services, regulatory support, and capacity for late-stage development and commercialization partnerships.

Growth Readiness With a mid-sized private profile and revenue in the lower to mid tens of millions, UBI may pursue strategic alliances or customer co-development deals with larger contract research organizations or pharma companies looking to diversify portfolios, particularly in immunotherapeutics, vaccines, and animal health products.